Antibodies to the first loop (ECL1) of CCR5 have been identified in human immunodeficiency virus (HIV)-exposed uninfected individuals (ESN) and in HIV-positive nonprogressing subjects. Thus, these antibodies may confer resistance against HIV infection. To define which amino acids are involved in antibody binding to CCR5, we performed a peptide-scanning assay and studied the immunogenicity of peptides in animal models. A panel of synthetic peptides spanning the CCR5-ECL1 region and displaying glycine or alanine substitutions was assayed for antibody binding with a pool of natural anti-CCR5 antibodies. We used mice and chickens to study the immunogenicity of mutagenized peptide. Structural characterization by nuclear magnetic resonance (NMR) spectroscopy and molecular dynamics simulations were performed to better understand the structural and conformational features of the mutagenized peptide. Amino acid substitutions in positions Ala95 and Ala96 (A 95 -A 96 ) increased antibody-peptide binding compared to that of the wild-type peptide (Asp 95 -Phe 96 ). The Ala95-96 peptide was shown to induce, in mice and chickens, antibodies displaying biological activity at very low concentrations. Strikingly, chicken antibodies to the Ala95-96 peptide specifically recognize human CCR5 molecules, downregulate receptors from lymphocytes, inhibit CCR5-dependent chemotaxis, and prevent infection by several R5 viruses, displaying 50% inhibitory concentrations of less than 3 ng/ml. NMR spectroscopy and molecular dynamics simulations proved the high flexibility of isolated epitopes and suggested that A 95 -A 96 substitutions determine a slightly higher tendency to generate helical conformations combined with a lower steric hindrance of the side chains in the peptides. These findings may be relevant to the induction of strong and efficient HIV-blocking antibodies.The CCR5 coreceptor is a seven-transmembrane (TM)-spanning receptor involved in chemokine signaling (13,35,38). It also is used as a viral coreceptor by human immunodeficiency virus (HIV), and it presumably mediates the first contacts between HIV and target host cells in mucosal sites, as CCR5-tropic HIV strains are generally the first in pioneering new hosts (6,8). The HIV-gp120 glycoprotein binds preferentially to the N terminus of CCR5 and the second extracellular region (18, 20). In addition, the second loop is mostly responsible for the binding of the endogenous chemokine peptides (42). Moreover, very recently a high level of immunogenicity has been found to both the N terminus and the first cysteine loop (49). Taken together, these findings suggest that the external domains of CCR5 are not clearly independent. In fact, it has been shown that CCR5 possesses a very dynamic equilibrium in the course of its interaction with Env proteins, which may induce different conformations in vivo (36). The binding of anti-gp120 immunoglobulins (Igs) also is known to alter the local conformation of viral and cellular proteins involved in the complex and therefore affect the whole proc...